You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 5,266,313

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,266,313
Title: Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
Abstract:Raccoon poxvirus, an organism that may be indigenous in nature, is established as a suitable substrate for insertion and expression of nucleotide coding sequence of heterolgous organisms. Two infectious raccoon poxvirus recombinants for expressing rabies virus surface spike glycoprotein (G) were produced by homologous recombination between raccoon poxvirus DNA and chimeric plasmids previously used for production of vaccinia virus recombinants by thymidine kinase insertional inactivation. Raccoons that were fed polyurethane baits loaded with raccoon poxvirus recombinant quickly developed high levels of rabies virus neutralizing antibodies and were protected when challenged with an otherwise lethal dose of raccoon rabies street virus. Dogs developed rabies virus neutralizing antibodies after feeding a vectored raccoon poxvirus recombinant in contrast to feeding a vaccinia: G recombinant that induced no rabies neutralizing antibodies. Cotton rats, skunks, mice and rabbits that were fed recombinant raccoon poxvirus developed variable levels of rabies neutralizing antibodies. All vaccinated cotton rats were protected from otherwise lethal rabies challenge.
Inventor(s): Esposito; Joseph J. (Atlanta, GA), Baer; George M. (Atlanta, GA)
Assignee: The United States of America as represented by the Department of Health (Washington, DC)
Application Number:07/829,597
Patent Claims:see list of patent claims

Details for Patent 5,266,313

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline Biologicals Sa RABAVERT rabies vaccine KIT 103334 1 2016-12-19   Start Trial The United States of America as represented by the Department of Health (Washington, DC) 2010-11-30 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.